news
Cardiologist questions new cholesterol drug enlicitide's market impact
Cardiologist Vishal Khetpal argues in STAT News that Merck's new cholesterol drug enlicitide, branded Lipfendra, likely won't change prescribing habits much, despite its mechanism. While it aims to lower LDL-C, Khetpal believes existing statin regimens are too entrenched for an immediate shift. This means you might not see it replacing your current meds anytime soon.
Cardiologist Vishal Khetpal argues in STAT News that Merck's new cholesterol drug enlicitide, branded Lipfendra, likely won't change prescribing habits much, despite its mechanism. While it aims to lower LDL-C, Khetpal believes existing statin regimens are too entrenched for an immediate shift. This means you might not see it replacing your current meds anytime soon.
The architecture take
This take by Dr. Khetpal is a dose of reality for anyone watching the cholesterol drug space. Yes, enlicitide (Lipfendra) works by blocking ANGPTL3, which is a different way to drop LDL-C than statins. But the idea that a new mechanism alone trumps decades of established prescribing patterns — and frankly, insurance coverage — is naive. Think about it: doctors are comfortable with what they know, and a new drug means new training, new side-effect profiles to learn, and battles with PBMs. The real beneficiaries aren't the patients who need it most, but the drug manufacturer who can now offer another option in an already crowded but lucrative market. The next thing to watch is how Merck tries to differentiate this beyond just mechanism — maybe a different administration route, or a specific patient profile it’s uniquely suited for.